5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Infusion O
reactions O
: O
Premedicate O
patients O
with O
glucocorticoid O
, O
acetaminophen O
, O
and O
anti-histamine O
. O

Monitor O
patients O
closely O
during O
infusions O
. O

Interrupt O
or O
discontinue O
infusion O
for O
reactions O
. O

( O
2.2 O
, O
5.3 O
) O
* O
Tumor O
Lysis O
Syndrome O
: O
Anticipate O
tumor O
lysis O
syndrome O
; O
premedicate O
with O
anti-hyperuricemics O
and O
adequate O
hydration O
especially O
for O
patients O
with O
high O
tumor O
burden O
and/or O
high O
circulating O
lymphocyte O
count O
. O

Correct O
electrolyte O
abnormalities O
, O
provide O
supportive O
care O
, O
and O
monitor O
renal O
function O
and O
fluid O
balance O
. O

( O
5.4 O
) O
* O
Neutropenia O
: O
Monitor O
for O
infection O
. O

( O
5.6 O
) O
* O
Thrombocytopenia O
: O
Monitor O
platelet O
counts O
and O
for O
bleeding O
. O

Management O
of O
hemorrhage O
may O
require O
blood O
product O
support O
. O

( O
5.7 O
) O
* O
Immunization O
: O
Do O
not O
administer O
live O
virus O
vaccines O
prior O
to O
or O
during O
GAZYVA O
treatment O
. O

( O
5.8 O
) O
5.1 O
Hepatitis O
B O
Virus O
Reactivation O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
in O
some O
cases O
resulting O
in O
fulminant B-NonOSE_AE
hepatitis I-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
treated O
with O
anti-CD20 O
antibodies O
such O
as O
GAZYVA O
. O

HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
who O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
( I-Not_AE_Candidate
HBsAg I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
and O
also O
in O
patients O
who O
are O
HBsAg O
negative O
but O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
core I-Not_AE_Candidate
antibody I-Not_AE_Candidate
( I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation O
has O
also O
occurred O
in O
patients O
who O
appear O
to O
have O
resolved O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
i.e. O
, O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
, O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
, O
and O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antibody I-Not_AE_Candidate
[ I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBs I-Not_AE_Candidate
] I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
. O

HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
defined O
as O
an O
abrupt O
increase O
in O
HBV O
replication O
manifesting O
as O
a O
rapid O
increase O
in O
serum O
HBV O
DNA O
level O
or O
detection O
of O
HBsAg O
in O
a O
person O
who O
was O
previously O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
and O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation B-NonOSE_AE
of I-NonOSE_AE
HBV I-NonOSE_AE
replication I-NonOSE_AE
is O
often O
followed O
by O
hepatitis B-NonOSE_AE
, O
i.e. O
, O
increase B-NonOSE_AE
in I-NonOSE_AE
transaminase I-NonOSE_AE
levels I-NonOSE_AE
and O
, O
in O
severe O
cases O
, O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
levels O
, O
liver B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
by O
measuring O
HBsAg O
and O
anti-HBc O
before O
initiating O
treatment O
with O
GAZYVA O
. O

For O
patients O
who O
show O
evidence O
of O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
HBsAg B-Not_AE_Candidate
positive I-Not_AE_Candidate
[ O
regardless O
of O
antibody O
status O
] O
or O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
but O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
, O
consult O
physicians O
with O
expertise O
in O
managing O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
regarding O
monitoring O
and O
consideration O
for O
HBV O
antiviral O
therapy O
. O

Monitor O
patients O
with O
evidence O
of O
current O
or O
prior O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
for O
clinical O
and O
laboratory O
signs O
of O
hepatitis B-NonOSE_AE
or O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
during O
and O
for O
several O
months O
following O
treatment O
with O
GAZYVA O
. O

HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
reported O
for O
other O
CD20-directed O
cytolytic O
antibodies O
following O
completion O
of O
therapy O
. O

In O
patients O
who O
develop O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
while O
receiving O
GAZYVA O
, O
immediately O
discontinue O
GAZYVA O
and O
any O
concomitant O
chemotherapy O
and O
institute O
appropriate O
treatment O
. O

Resumption O
of O
GAZYVA O
in O
patients O
whose O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
resolves O
should O
be O
discussed O
with O
physicians O
with O
expertise O
in O
managing O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
. O

Insufficient O
data O
exist O
regarding O
the O
safety O
of O
resuming O
GAZYVA O
in O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

5.2 O
Progressive O
Multifocal O
Leukoencephalopathy O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
resulting O
in O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( O
PML O
) O
, O
which O
can O
be O
fatal O
, O
was O
observed O
in O
patients O
treated O
with O
GAZYVA O
. O

Consider O
the O
diagnosis O
of O
PML B-NonOSE_AE
in O
any O
patient O
presenting O
with O
new O
onset O
or O
changes B-NonOSE_AE
to I-NonOSE_AE
preexisting I-NonOSE_AE
neurologic I-NonOSE_AE
manifestations I-NonOSE_AE
. O

Evaluation O
of O
PML B-NonOSE_AE
includes O
, O
but O
is O
not O
limited O
to O
, O
consultation O
with O
a O
neurologist O
, O
brain O
MRI O
, O
and O
lumbar O
puncture O
. O

Discontinue O
GAZYVA O
therapy O
and O
consider O
discontinuation O
or O
reduction O
of O
any O
concomitant O
chemotherapy O
or O
immunosuppressive O
therapy O
in O
patients O
who O
develop O
PML B-NonOSE_AE
. O

5.3 O
Infusion O
Reactions O
GAZYVA O
can O
cause O
severe O
and O
life-threatening O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Two O
thirds O
of O
patients O
experienced O
a O
reaction O
to O
the O
first O
1000 O
mg O
infused O
of O
GAZYVA O
. O

Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
can O
also O
occur O
with O
subsequent O
infusions O
. O

Symptoms O
may O
include O
hypotension B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
and O
respiratory B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
bronchospasm B-NonOSE_AE
, O
larynx B-NonOSE_AE
and O
throat O
irritation I-NonOSE_AE
, O
wheezing B-NonOSE_AE
, O
laryngeal B-NonOSE_AE
edema I-NonOSE_AE
) O
. O

Other O
common O
symptoms O
include O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
hypertension B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
pyrexia B-NonOSE_AE
, O
and O
chills B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Premedicate O
patients O
with O
acetaminophen O
, O
antihistamine O
, O
and O
a O
glucocorticoid O
. O

Institute O
medical O
management O
( O
e.g. O
, O
glucocorticoids O
, O
epinephrine O
, O
bronchodilators O
, O
and/or O
oxygen O
) O
for O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
as O
needed O
. O

Closely O
monitor O
patients O
during O
the O
entire O
infusion O
. O

Infusion B-NonOSE_AE
reactions I-NonOSE_AE
within O
24 O
hours O
of O
receiving O
GAZYVA O
have O
occurred O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

For O
patients O
with O
any O
Grade O
4 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
including O
but O
not O
limited O
to O
anaphylaxis B-NonOSE_AE
, O
acute O
life B-NonOSE_AE
- I-NonOSE_AE
threatening I-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
, O
or O
other O
life-threatening O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
: O
Stop O
the O
GAZYVA O
infusion O
. O

Permanently O
discontinue O
GAZYVA O
therapy O
. O

For O
patients O
with O
Grade O
1 O
, O
2 O
, O
or O
3 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
: O
Interrupt O
GAZYVA O
for O
Grade O
3 O
reactions O
until O
resolution O
of O
symptoms O
. O

Interrupt O
or O
reduce O
the O
rate O
of O
the O
infusion O
for O
Grade O
1 O
or O
2 O
reactions O
and O
manage O
symptoms O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

For O
patients O
with O
preexisting O
cardiac B-Not_AE_Candidate
or O
pulmonary B-Not_AE_Candidate
conditions I-Not_AE_Candidate
, O
monitor O
more O
frequently O
throughout O
the O
infusion O
and O
the O
post-infusion O
period O
since O
they O
may O
be O
at O
greater O
risk O
of O
experiencing O
more O
severe O
reactions O
. O

Hypotension B-NonOSE_AE
may O
occur O
as O
part O
of O
the O
GAZYVA O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Consider O
withholding O
antihypertensive O
treatments O
for O
12 O
hours O
prior O
to O
, O
during O
each O
GAZYVA O
infusion O
, O
and O
for O
the O
first O
hour O
after O
administration O
until O
blood O
pressure O
is O
stable O
. O

For O
patients O
at O
increased O
risk O
of O
hypertensive B-Not_AE_Candidate
crisis I-Not_AE_Candidate
, O
consider O
the O
benefits O
versus O
the O
risks O
of O
withholding O
their O
antihypertensive O
medication O
as O
is O
suggested O
here O
. O

5.4 O
Tumor O
Lysis O
Syndrome O
Acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
, O
hyperkalemia B-NonOSE_AE
, O
hypocalcemia B-NonOSE_AE
, O
hyperuricemia B-NonOSE_AE
, O
and/or O
hyperphosphatemia B-NonOSE_AE
from O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
TLS O
) O
can O
occur O
within O
12-24 O
hours O
after O
the O
first O
infusion O
. O

Patients O
with O
high B-Not_AE_Candidate
tumor I-Not_AE_Candidate
burden I-Not_AE_Candidate
and/or O
high B-Not_AE_Candidate
circulating O
lymphocyte I-Not_AE_Candidate
count I-Not_AE_Candidate
( O
> O
25 O
* O
10 O
9 O
/L O
) O
are O
at O
greater O
risk O
for O
TLS B-NonOSE_AE
and O
should O
receive O
appropriate O
tumor O
lysis O
prophylaxis O
with O
anti-hyperuricemics O
( O
e.g. O
, O
allopurinol O
) O
and O
hydration O
beginning O
12-24 O
hours O
prior O
to O
the O
infusion O
of O
GAZYVA O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

For O
treatment O
of O
TLS B-NonOSE_AE
, O
correct O
electrolyte B-NonOSE_AE
abnormalities I-NonOSE_AE
, O
monitor O
renal O
function O
and O
fluid O
balance O
, O
and O
administer O
supportive O
care O
, O
including O
dialysis O
as O
indicated O
. O

5.5 O
Infections O
Serious O
bacterial B-OSE_Labeled_AE
, O
fungal O
, O
and O
new O
or O
reactivated O
viral O
infections I-OSE_Labeled_AE
can O
occur O
during O
and O
following O
GAZYVA O
therapy O
. O

Fatal O
infections B-OSE_Labeled_AE
have O
been O
reported O
with O
GAZYVA O
. O

Do O
not O
administer O
GAZYVA O
to O
patients O
with O
an O
active B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Patients O
with O
a O
history O
of O
recurring O
or O
chronic B-Not_AE_Candidate
infections I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
of O
infection B-NonOSE_AE
. O

5.6 O
Neutropenia O
GAZYVA O
in O
combination O
with O
chlorambucil O
caused O
Grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
in O
33 O
% O
of O
patients O
in O
the O
trial O
. O

Patients O
with O
Grade O
3 O
to O
4 O
neutropenia B-NonOSE_AE
should O
be O
monitored O
frequently O
with O
regular O
laboratory O
tests O
until O
resolution O
. O

Anticipate O
, O
evaluate O
, O
and O
treat O
any O
symptoms O
or O
signs O
of O
developing O
infection B-NonOSE_AE
. O

Neutropenia B-OSE_Labeled_AE
can O
also O
be O
of O
late O
onset O
( O
occurring O
more O
than O
28 O
days O
after O
completion O
of O
treatment O
) O
and/or O
prolonged O
( O
lasting O
longer O
than O
28 O
days O
) O
. O

Patients O
with O
neutropenia B-NonOSE_AE
are O
strongly O
recommended O
to O
receive O
antimicrobial O
prophylaxis O
throughout O
the O
treatment O
period O
. O

Antiviral O
and O
antifungal O
prophylaxis O
should O
be O
considered O
. O

5.7 O
Thrombocytopenia O
GAZYVA O
in O
combination O
with O
chlorambucil O
caused O
Grade O
3 O
or O
4 O
thrombocytopenia B-OSE_Labeled_AE
in O
10 O
% O
of O
patients O
in O
the O
trial O
. O

In O
4 O
% O
of O
patients O
, O
GAZYVA O
caused O
acute O
thrombocytopenia B-OSE_Labeled_AE
occurring O
within O
24 O
hours O
after O
the O
GAZYVA O
infusion O
. O

Fatal O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
during O
Cycle O
1 O
have O
also O
been O
reported O
in O
patients O
treated O
with O
GAZYVA O
. O

Monitor O
all O
patients O
frequently O
for O
thrombocytopenia B-NonOSE_AE
and O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
, O
especially O
during O
the O
first O
cycle O
. O

In O
patients O
with O
Grade O
3 O
or O
4 O
thrombocytopenia B-NonOSE_AE
, O
monitor O
platelet O
counts O
more O
frequently O
until O
resolution O
and O
consider O
subsequent O
dose O
delays O
of O
GAZYVA O
and O
chlorambucil O
or O
dose O
reductions O
of O
chlorambucil O
. O

Transfusion O
of O
blood O
products O
( O
i.e. O
, O
platelet O
transfusion O
) O
may O
be O
necessary O
. O

Consider O
withholding O
concomitant O
medications O
which O
may O
increase B-NonOSE_AE
bleeding I-NonOSE_AE
risk I-NonOSE_AE
( O
platelet O
inhibitors O
, O
anticoagulants O
) O
, O
especially O
during O
the O
first O
cycle O
. O

5.8 O
Immunization O
The O
safety O
and O
efficacy O
of O
immunization O
with O
live O
or O
attenuated O
viral O
vaccines O
during O
or O
following O
GAZYVA O
therapy O
has O
not O
been O
studied O
. O

Immunization O
with O
live O
virus O
vaccines O
is O
not O
recommended O
during O
treatment O
and O
until O
B-cell O
recovery O
. O

